Results 201 to 210 of about 3,374,023 (302)

Risk of Cancer With Hormone Replacement Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Hormone replacement therapy (HRT) remains the cornerstone of menopausal symptom management, effectively alleviating vasomotor symptoms and genitourinary syndrome, whilst mitigating long‐term risks such as osteoporosis. However, despite an increasing body of evidence on the relative safety of HRT, earlier studies that demonstrated an increased ...
Gabriella Yongue, Zachary Nash, Vikram Talaulikar, Shibani Nicum   +3 more
wiley   +1 more source

Reproductive Challenges of the Ageing Female: A Comprehensive Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Changes in societal norms over the last few decades have resulted in novel family planning trends, notably delayed childbearing and increased maternal age at the birth of the first child. Despite advances in reproductive medicine, ageing poses significant challenges.
Sofia Bitzika, Meletios P. Nigdelis, Angelos Daniilidis, Erich‐Franz Solomayer, Irene Lambrinoudaki, Efstratios M. Kolibianakis, Dimitrios G. Goulis   +6 more
wiley   +1 more source

Evaluation of Punicalagin as a multi‑targeted therapeutic agent against endometrial cancer. [PDF]

Int J Oncol
Bhutta ZA, Ahn D, Lee HK, Choi KC.
europepmc   +1 more source

Comparative Efficacy of Elinzanetant Versus Other Non‐Hormonal Pharmaceutical Therapies for the Treatment of Moderate‐to‐Severe Vasomotor Symptoms Associated With Menopause: A Network Meta‐Analysis

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Background Elinzanetant, a novel, dual neurokinin‐targeted therapy, has been approved in various geographies for the treatment of moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Objective To compare the efficacy of elinzanetant with non‐hormonal pharmaceutical treatments (nHT) in alleviating VMS.
Piotr Wojciechowski, Klaudia Kolonko, Andromachi Giannopoulou, Beata Smela, Elżbieta Olewinska, Kristina Rosa Bolling, Jenifer Sassarini, Lee P. Shulman, Vikram Talaulikar   +8 more
wiley   +1 more source

Expression of estrogen receptor and progesterone receptor in endometrial cancer and their correlations with clinicopathological features. [PDF]

Front Oncol
Li EP, Hong Y, Wei JZ, Li CK, Liang HQ.
europepmc   +1 more source

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen monotherapy, though historically underutilized, represents a viable alternative in this population. This narrative review
Chloe Thomas, Olivia Carere, Lauren Clarfield, Michelle Jacobson   +3 more
wiley   +1 more source

MRI-Based Radiomics Model for Predicting Eligibility for Conservative Management of Endometrial Cancer. [PDF]

Cancer Med
Ding S, Meng H, Cui X, Yang Y, Xing L, Zuo Z, Liu C, Xue L, Yin X.   +8 more
europepmc   +1 more source

Peritoneal Fluid‐Derived Small Extracellular Vesicle Proteins as Potential Biomarkers for Endometriosis: A Case–Control Study

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Objective To demonstrate the presence of peritoneal fluid (PF)‐derived small extracellular vesicles (sEVs) in endometriosis and control samples, to characterise their protein content and to define endometriosis‐specific biomarkers within the sEV proteome. Design Case–control experimental study. Setting Academic endometriosis centre.
Hannah M. Nazri, Roman Fischer, Joel Steele, Sanjiv Manek, Kavita S. Subramaniam, Benedikt M. Kessler, Krina T. Zondervan, Thomas T. Tapmeier, Christian M. Becker   +8 more
wiley   +1 more source